NASDAQ:TBPH - Theravance Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.14 +0.12 (+0.52 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$23.02
Today's Range$23.00 - $23.76
52-Week Range$21.27 - $43.44
Volume226,600 shs
Average Volume240,350 shs
Market Capitalization$1.26 billion
P/E Ratio-4.25
Dividend YieldN/A
Beta1.81

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBPH
CUSIPN/A
Phone650-808-6000

Debt

Debt-to-Equity Ratio3.53
Current Ratio4.25
Quick Ratio4.08

Price-To-Earnings

Trailing P/E Ratio-4.25
Forward P/E Ratio-4.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.39 million
Price / Sales82.47
Cash FlowN/A
Price / CashN/A
Book Value$1.16 per share
Price / Book19.95

Profitability

EPS (Most Recent Fiscal Year)($5.45)
Net Income$-285,400,000.00
Net Margins-1,383.47%
Return on Equity-188.96%
Return on Assets-58.47%

Miscellaneous

Employees340
Outstanding Shares54,850,000

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma (NASDAQ:TBPH) announced its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.26) by $0.04. The biopharmaceutical company earned $8.32 million during the quarter, compared to analysts' expectations of $5.74 million. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. View Theravance Biopharma's Earnings History.

What price target have analysts set for TBPH?

6 brokers have issued 1-year target prices for Theravance Biopharma's stock. Their forecasts range from $22.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $39.6667 in the next year. View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:
  • 1. Needham & Company LLC analysts commented, "Theravance provided a quarterly corporate update yesterday. Mgmt guided for TD-9855 data in Neurogenic Orthostatic Hypotension (NOH) in Jul 2018 (was 2Q18). Impact on symptoms (dizziness) through 4wks will be key. There are limitations to the trial, however, including a small number of patients and no placebo arm. Nevertheless, mgmt is optimistic for Phase 3 initiation by YE18. FDA reportedly requiring a large safety trial for velusetrag, prompting Theravance to stop development in the U.S. Collaborator Alfasigma consequently exercised its option for WW rights and will pursue development in EU. TD-1473 trial initiations in Disease are still on track for 2H18. Reiterate BUY, but reducing price target to $40 (was $45) to reflect decision not to develop velusetrag in U.S." (5/9/2018)
  • 2. According to Zacks Investment Research, "Theravance has a single marketed product in its portfolio called Vibativ. Moreover, its pipeline programs are targeting highly competitive therapeutic areas. Also, any agreement termination might be a huge setback for the company as in the past. Shares of the company have underperformed the industry in a year’s time. However, we are upbeat about Theravance’s efforts to expand Vibativ’s label, which if approved for additional indications, would be commercially significant. Moreover, the company’s regulatory filing for revefenacin for treating chronic obstructive pulmonary disease was accepted by the FDA in January 2018 with a response expected by this year-end. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has negative record of earnings surprises in recent quarters." (5/1/2018)
  • 3. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered)." (2/27/2018)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 58)
  • Ms. Renée D. Galá, Sr. VP, CFO & Treasurer (Age 46)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. Sharathchandra S. Hegde, Sr. VP of Research (Age 54)
  • Dr. Phillip D. Worboys, Sr. VP of Translational Science (Age 48)

Has Theravance Biopharma been receiving favorable news coverage?

News coverage about TBPH stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Theravance Biopharma earned a daily sentiment score of 0.21 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (19.89%), BlackRock Inc. (6.54%), Northern Trust Corp (0.94%), Schwab Charles Investment Management Inc. (0.38%), Senzar Asset Management LLC (0.34%) and Jane Street Group LLC (0.26%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Frank Pasqualone, Henrietta Fore, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Which institutional investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Legal & General Group Plc, Teacher Retirement System of Texas, Old West Investment Management LLC and California Public Employees Retirement System. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer and Renee D Gala. View Insider Buying and Selling for Theravance Biopharma.

Which institutional investors are buying Theravance Biopharma stock?

TBPH stock was purchased by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Jane Street Group LLC, Millennium Management LLC, Hound Partners LLC, Senzar Asset Management LLC, Alps Advisors Inc., Schwab Charles Investment Management Inc. and Xact Kapitalforvaltning AB. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $23.14.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.26 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


MarketBeat Community Rating for Theravance Biopharma (TBPH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Theravance Biopharma (NASDAQ:TBPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Theravance Biopharma in the last 12 months. Their average twelve-month price target is $39.6667, suggesting that the stock has a possible upside of 71.42%. The high price target for TBPH is $55.00 and the low price target for TBPH is $22.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.6667$43.3333$42.8333$42.6667
Price Target Upside: 71.42% upside82.84% upside53.63% upside51.35% upside

Theravance Biopharma (NASDAQ:TBPH) Consensus Price Target History

Price Target History for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018Cantor FitzgeraldSet Price TargetBuy$55.00LowView Rating Details
5/9/2018Needham & Company LLCReiterated RatingBuy$40.00LowView Rating Details
5/9/2018Leerink SwannSet Price TargetBuy$41.00 ➝ $31.00HighView Rating Details
3/29/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$45.00MediumView Rating Details
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$45.00MediumView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/3/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Theravance Biopharma (NASDAQ:TBPH) Earnings History and Estimates Chart

Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) Earnings Estimates

2018 EPS Consensus Estimate: ($5.20)
2019 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.40)($1.40)($1.40)
Q2 20182($1.28)($1.25)($1.27)
Q3 20182($1.21)($1.20)($1.21)
Q4 20182($1.33)($1.33)($1.33)
Q1 20191($1.05)($1.05)($1.05)
Q2 20191($1.00)($1.00)($1.00)
Q3 20191($1.05)($1.05)($1.05)
Q4 20191($0.95)($0.95)($0.95)

Theravance Biopharma (NASDAQ TBPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1($1.2590)($1.22)$5.74 million$8.32 millionViewN/AView Earnings Details
2/27/2018Q4 2017($1.15)($1.64)$3.71 million$4.52 millionViewN/AView Earnings Details
11/7/2017Q3 2017($1.22)($1.27)$3.60 million$4.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.13)($1.27)$4.06 million$3.51 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
11/8/2016Q3 2016($0.95)($0.73)$16.41 million$19.08 millionViewN/AView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
5/7/2015Q1 2015($1.57)($1.29)$7.55 million$20.40 millionViewN/AView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Theravance Biopharma (NASDAQ:TBPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Theravance Biopharma (NASDAQ TBPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 85.94%
Insider Trading History for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ TBPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Burton G MalkielDirectorBuy1,000$22.54$22,540.0056,757View SEC Filing  
5/18/2018Renee D GalaCFOSell10,000$24.29$242,900.00236,022View SEC Filing  
9/6/2017Bradford J ShaferEVPSell14,670$30.77$451,395.90134,327View SEC Filing  
8/21/2017Frank PasqualoneSVPBuy4,000$26.34$105,360.00213,180View SEC Filing  
8/11/2017Henrietta ForeDirectorBuy6,000$23.99$143,940.0024,000View SEC Filing  
8/11/2017Rick E WinninghamCEOBuy10,000$24.50$245,000.00866,377View SEC Filing  
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20163,895View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52163,895View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09188,293View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12241,686View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73197,391View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Theravance Biopharma (NASDAQ TBPH) News Headlines

Source:
DateHeadline
Theravance Biopharma (TBPH) Given a $55.00 Price Target at Cantor FitzgeraldTheravance Biopharma (TBPH) Given a $55.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 6:30 PM
Equities Analysts Issue Forecasts for Theravance Biopharmas FY2019 Earnings (TBPH)Equities Analysts Issue Forecasts for Theravance Biopharma's FY2019 Earnings (TBPH)
www.americanbankingnews.com - May 24 at 9:36 AM
Insider Buying: Theravance Biopharma (TBPH) Director Buys 1,000 Shares of StockInsider Buying: Theravance Biopharma (TBPH) Director Buys 1,000 Shares of Stock
www.americanbankingnews.com - May 23 at 8:34 PM
Insider Selling: Theravance Biopharma (TBPH) CFO Sells 10,000 Shares of StockInsider Selling: Theravance Biopharma (TBPH) CFO Sells 10,000 Shares of Stock
www.americanbankingnews.com - May 22 at 7:46 PM
$9.97 Million in Sales Expected for Theravance Biopharma (TBPH) This Quarter$9.97 Million in Sales Expected for Theravance Biopharma (TBPH) This Quarter
www.americanbankingnews.com - May 22 at 1:54 AM
Zacks: Analysts Expect Theravance Biopharma (TBPH) to Post -$1.24 Earnings Per ShareZacks: Analysts Expect Theravance Biopharma (TBPH) to Post -$1.24 Earnings Per Share
www.americanbankingnews.com - May 20 at 11:16 PM
Theravance Biopharma (TBPH) Given Average Recommendation of "Hold" by BrokeragesTheravance Biopharma (TBPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 1:34 AM
Theravance Biopharma (TBPH) Downgraded by BidaskClubTheravance Biopharma (TBPH) Downgraded by BidaskClub
www.americanbankingnews.com - May 18 at 1:19 PM
Theravance Biopharma (TBPH) Upgraded by BidaskClub to HoldTheravance Biopharma (TBPH) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - May 11 at 7:53 PM
Piper Jaffray Weighs in on Theravance Biopharmas Q2 2018 Earnings (TBPH)Piper Jaffray Weighs in on Theravance Biopharma's Q2 2018 Earnings (TBPH)
www.americanbankingnews.com - May 11 at 9:01 AM
Leerink Swann Comments on Theravance Biopharmas Q2 2018 Earnings (TBPH)Leerink Swann Comments on Theravance Biopharma's Q2 2018 Earnings (TBPH)
www.americanbankingnews.com - May 11 at 9:01 AM
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare ConferenceTheravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 10 at 9:42 AM
Edited Transcript of TBPH earnings conference call or presentation 8-May-18 9:00pm GMTEdited Transcript of TBPH earnings conference call or presentation 8-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 9:42 AM
Piper Jaffray Comments on Theravance Biopharmas FY2022 Earnings (TBPH)Piper Jaffray Comments on Theravance Biopharma's FY2022 Earnings (TBPH)
www.americanbankingnews.com - May 10 at 9:18 AM
Theravance Biopharmas (TBPH) "Buy" Rating Reaffirmed at Needham & Company LLCTheravance Biopharma's (TBPH) "Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - May 9 at 9:42 PM
Theravance Biopharma (TBPH) Rating Reiterated by Leerink SwannTheravance Biopharma (TBPH) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - May 9 at 5:11 PM
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/YTheravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
finance.yahoo.com - May 9 at 4:30 PM
Theravance Biopharma (TBPH) Posts  Earnings Results, Beats Estimates By $0.04 EPSTheravance Biopharma (TBPH) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 9 at 1:31 PM
Theravance Biopharma beats by $0.04, beats on revenueTheravance Biopharma beats by $0.04, beats on revenue
seekingalpha.com - May 9 at 9:32 AM
Theravance Biopharmas (TBPH) CEO Rick Winningham on Q1 2018 Results - Earnings Call TranscriptTheravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:32 AM
Theravance Bio: 1Q Earnings SnapshotTheravance Bio: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:32 AM
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business UpdateTheravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 8 at 4:26 PM
Theravance Biopharma (TBPH) Expected to Post Quarterly Sales of $5.74 MillionTheravance Biopharma (TBPH) Expected to Post Quarterly Sales of $5.74 Million
www.americanbankingnews.com - May 5 at 3:39 AM
-$1.29 Earnings Per Share Expected for Theravance Biopharma (TBPH) This Quarter-$1.29 Earnings Per Share Expected for Theravance Biopharma (TBPH) This Quarter
www.americanbankingnews.com - May 3 at 6:17 PM
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - May 1 at 4:23 PM
Zacks Investment Research Downgrades Theravance Biopharma (TBPH) to SellZacks Investment Research Downgrades Theravance Biopharma (TBPH) to Sell
www.americanbankingnews.com - May 1 at 2:02 PM
Theravance Biopharma (TBPH) Stock Rating Upgraded by ValuEngineTheravance Biopharma (TBPH) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 27 at 12:13 PM
Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for Treatment of COPD PatientsTheravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
www.streetinsider.com - April 25 at 9:36 AM
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD PatientsTheravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
finance.yahoo.com - April 25 at 9:36 AM
Theravance Biopharma (TBPH) Receives Consensus Recommendation of "Hold" from AnalystsTheravance Biopharma (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 25 at 1:52 AM
Theravance Biopharma (TBPH) Upgraded at BidaskClubTheravance Biopharma (TBPH) Upgraded at BidaskClub
www.americanbankingnews.com - April 25 at 12:24 AM
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ ConferenceTheravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
finance.yahoo.com - April 23 at 9:12 AM
Theravance Biopharma (TBPH) Downgraded by ValuEngineTheravance Biopharma (TBPH) Downgraded by ValuEngine
www.americanbankingnews.com - April 20 at 12:24 AM
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD PatientsTheravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
finance.yahoo.com - April 19 at 4:37 PM
Zacks: Analysts Anticipate Theravance Biopharma (TBPH) Will Post Quarterly Sales of $5.74 MillionZacks: Analysts Anticipate Theravance Biopharma (TBPH) Will Post Quarterly Sales of $5.74 Million
www.americanbankingnews.com - April 18 at 3:56 AM
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ ConferenceTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
finance.yahoo.com - April 17 at 9:50 AM
Theravance Biopharma (TBPH) Expected to Post Earnings of -$1.29 Per ShareTheravance Biopharma (TBPH) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM
Theravance Biopharma (TBPH) Cut to "Sell" at ValuEngineTheravance Biopharma (TBPH) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 10:47 AM
Theravance Biopharma (TBPH) Upgraded at ValuEngineTheravance Biopharma (TBPH) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:56 AM
Theravance Biopharma (TBPH) Given "Sell" Rating at Robert W. BairdTheravance Biopharma (TBPH) Given "Sell" Rating at Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM
Theravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $6.86 MillionTheravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $6.86 Million
www.americanbankingnews.com - April 1 at 4:00 AM
Theravance Biopharma Inc (TBPH) Receives Consensus Rating of "Hold" from BrokeragesTheravance Biopharma Inc (TBPH) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.31 Per ShareTheravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.31 Per Share
www.americanbankingnews.com - March 30 at 1:18 PM
Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?
finance.yahoo.com - March 30 at 9:35 AM
Theravance Biopharma (TBPH) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowTheravance Biopharma (TBPH) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:26 PM
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 29 at 4:26 PM
Theravance Biopharma (TBPH) Coverage Initiated at Piper JaffrayTheravance Biopharma (TBPH) Coverage Initiated at Piper Jaffray
www.americanbankingnews.com - March 29 at 11:16 AM
ValuEngine Lowers Theravance Biopharma (TBPH) to SellValuEngine Lowers Theravance Biopharma (TBPH) to Sell
www.americanbankingnews.com - March 28 at 10:22 PM
Theravance Biopharma (TBPH) Rating Lowered to Strong Sell at BidaskClubTheravance Biopharma (TBPH) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:54 PM
Theravance Biopharma to Present at the 17th Annual Needham Healthcare ConferenceTheravance Biopharma to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 10:40 AM

SEC Filings

Theravance Biopharma (NASDAQ:TBPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Theravance Biopharma (NASDAQ:TBPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Theravance Biopharma (NASDAQ TBPH) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.